JPWO2020002701A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020002701A5 JPWO2020002701A5 JP2021500159A JP2021500159A JPWO2020002701A5 JP WO2020002701 A5 JPWO2020002701 A5 JP WO2020002701A5 JP 2021500159 A JP2021500159 A JP 2021500159A JP 2021500159 A JP2021500159 A JP 2021500159A JP WO2020002701 A5 JPWO2020002701 A5 JP WO2020002701A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- chain
- alkenyl
- aryl
- linked
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000547 substituted alkyl group Chemical group 0.000 claims 25
- 125000003342 alkenyl group Chemical group 0.000 claims 23
- 125000000304 alkynyl group Chemical group 0.000 claims 23
- 125000003118 aryl group Chemical group 0.000 claims 23
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- -1 anthrasenyl Chemical group 0.000 claims 11
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 8
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 8
- 125000003107 substituted aryl group Chemical group 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000004385 trihaloalkyl group Chemical group 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 3
- 229940124530 sulfonamide Drugs 0.000 claims 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 2
- JHTLPSNDZNHQDZ-UHFFFAOYSA-N 1,3-benzodioxole-5-sulfonamide Chemical compound NS(=O)(=O)C1=CC=C2OCOC2=C1 JHTLPSNDZNHQDZ-UHFFFAOYSA-N 0.000 claims 1
- KTFDYVNEGTXQCV-UHFFFAOYSA-N 2-Thiophenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CS1 KTFDYVNEGTXQCV-UHFFFAOYSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 229940122815 Aromatase inhibitor Drugs 0.000 claims 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- HTNOOKMPGKXVKA-UHFFFAOYSA-N N-[1-[2-fluoro-4-(2-methoxyphenyl)phenyl]-2-oxopiperidin-3-yl]-1,3-benzodioxole-5-sulfonamide Chemical compound FC=1C=C(C=CC=1N1C(C(CCC1)NS(=O)(=O)C1=CC2=C(OCO2)C=C1)=O)C1=C(C=CC=C1)OC HTNOOKMPGKXVKA-UHFFFAOYSA-N 0.000 claims 1
- MMYSAFVSAUKXLR-UHFFFAOYSA-N N-[1-[2-fluoro-4-(2-methoxyphenyl)phenyl]-2-oxopiperidin-3-yl]-1-benzofuran-2-sulfonamide Chemical compound FC=1C=C(C=CC=1N1C(C(CCC1)NS(=O)(=O)C=1OC2=C(C=1)C=CC=C2)=O)C1=C(C=CC=C1)OC MMYSAFVSAUKXLR-UHFFFAOYSA-N 0.000 claims 1
- VGTUQHLTLNSPLS-UHFFFAOYSA-N N-[1-[2-fluoro-4-(2-methoxyphenyl)phenyl]-2-oxopiperidin-3-yl]-3,5-dimethyl-1,2-oxazole-4-sulfonamide Chemical compound FC=1C=C(C=CC=1N1C(C(CCC1)NS(=O)(=O)C=1C(=NOC=1C)C)=O)C1=C(C=CC=C1)OC VGTUQHLTLNSPLS-UHFFFAOYSA-N 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 229930013930 alkaloid Natural products 0.000 claims 1
- 150000003797 alkaloid derivatives Chemical class 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000002280 anti-androgenic effect Effects 0.000 claims 1
- 239000000051 antiandrogen Substances 0.000 claims 1
- 239000013059 antihormonal agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003972 antineoplastic antibiotic Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 239000003886 aromatase inhibitor Substances 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 235000010290 biphenyl Nutrition 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 230000029087 digestion Effects 0.000 claims 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 1
- 238000009162 epigenetic therapy Methods 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 239000003504 photosensitizing agent Substances 0.000 claims 1
- 231100000614 poison Toxicity 0.000 claims 1
- 230000007096 poisonous effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 210000004500 stellate cell Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382485.3A EP3586847A1 (en) | 2018-06-29 | 2018-06-29 | Compounds for use in preventing or treating cancer |
| EP18382485.3 | 2018-06-29 | ||
| PCT/EP2019/067557 WO2020002701A1 (en) | 2018-06-29 | 2019-07-01 | Compounds for use in preventing or treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021530472A JP2021530472A (ja) | 2021-11-11 |
| JPWO2020002701A5 true JPWO2020002701A5 (es) | 2022-07-11 |
| JP7451485B2 JP7451485B2 (ja) | 2024-03-18 |
Family
ID=62842045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500159A Active JP7451485B2 (ja) | 2018-06-29 | 2019-07-01 | 癌の予防または治療に使用するための化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12006311B2 (es) |
| EP (2) | EP3586847A1 (es) |
| JP (1) | JP7451485B2 (es) |
| ES (1) | ES2938412T3 (es) |
| PT (1) | PT3813832T (es) |
| WO (1) | WO2020002701A1 (es) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6710058B2 (en) * | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
| TW200307667A (en) * | 2002-05-06 | 2003-12-16 | Bristol Myers Squibb Co | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors |
-
2018
- 2018-06-29 EP EP18382485.3A patent/EP3586847A1/en not_active Withdrawn
-
2019
- 2019-07-01 PT PT197335201T patent/PT3813832T/pt unknown
- 2019-07-01 ES ES19733520T patent/ES2938412T3/es active Active
- 2019-07-01 WO PCT/EP2019/067557 patent/WO2020002701A1/en active Application Filing
- 2019-07-01 JP JP2021500159A patent/JP7451485B2/ja active Active
- 2019-07-01 EP EP19733520.1A patent/EP3813832B1/en active Active
- 2019-07-01 US US17/256,837 patent/US12006311B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2155045T3 (es) | Inhibicion de la quinasa raf utilizando ureas heterociclicas sustituidas con arilo y heteroarilo. | |
| ES2400070T3 (es) | Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos | |
| ES2821790T3 (es) | Moduladores de la vía de estrés integrada | |
| ES2540561T3 (es) | N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa | |
| TWI222447B (en) | 2-amino-thiazole derivatives, process for their preparation, and their use as antitumor agents | |
| JP2022020003A5 (es) | ||
| JP2014506599A5 (es) | ||
| AU2015306662A1 (en) | Compounds and methods for inhibiting histone demethylases | |
| ES2760898T3 (es) | Método de tratamiento o prevención de enfermedades mediadas por Ras | |
| TW200524575A (en) | Biaryl linked hydroxamates: preparation and pharmaceutical applications | |
| JP2018502900A5 (es) | ||
| RU2770824C2 (ru) | Противоопухолевый агент | |
| ES2911040T3 (es) | Nuevos derivados de heteroaril amida como inhibidores selectivos de histona deacetilasa 1 y 2 (HDAC1/2) | |
| JP2009514899A5 (es) | ||
| RU2005133994A (ru) | Оксимные производные и их применение в качестве фармацевтически активных агентов | |
| ES2389678T3 (es) | Un inhibidor de la quinasa C-Kit para su uso en el tratamiento de tumores del estroma gastrointestinal o mastocitosis | |
| JP2020527173A5 (es) | ||
| US20210395242A1 (en) | Heterocyclic compounds as ahr modulators | |
| BR112021005171A2 (pt) | derivados de quinuclidina-3-ona e seu uso em tratamento de câncer | |
| WO2007132228A1 (en) | Combination of cndac with a 2-substituted-4-heter0aryl-pyrimidine amine and use thereof in the treatment of a proliferative disorder | |
| JP7301856B2 (ja) | インドールアミン－２，３－ジオキシゲナーゼ阻害剤およびその調製方法と使用 | |
| RU2011108485A (ru) | Новые (поли)аминоалкиламиноалкиламидные, алкилмочевинные или алкилсульфонамидные производные эпиподофиллотоксина, способ их получения и их применение в терапии в качестве противораковых средств | |
| JP2020516616A5 (es) | ||
| JP6216326B2 (ja) | 炎症および癌の処置において有用なビスアリールスルホンアミド | |
| JP2014512362A5 (es) |